When the body’s DNA repair system carries mutations, cells lose their ability to correct errors that naturally occur during DNA copying, leading to rapid accumulation of genetic mistakes and increasing cancer risk.

How Treatment Approaches Support People with DNA Repair Gene Mutations

DNA mismatch repair gene mutations disrupt one of the body’s most important protective systems. Normally, special proteins work constantly to fix tiny mistakes that happen when cells copy their DNA before dividing. These mistakes are completely natural and happen to everyone, but healthy repair systems catch and correct them. When someone inherits mutations in genes like MLH1, MSH2, MSH6, or PMS2, this repair system doesn’t work properly. Without functioning repair machinery, errors accumulate much faster than normal—sometimes 50 to 1000 times faster than in people with healthy repair genes.^[2]

The goal of treatment is not to fix the genetic mutation itself, which remains present in every cell of the body from birth. Instead, treatment focuses on managing the consequences of having a faulty repair system. This includes careful monitoring to catch cancers early when they’re most treatable, using preventive surgeries in some cases, and taking advantage of how these particular cancers respond differently to certain treatments, especially newer immunotherapy approaches. Treatment plans are highly personalized and depend on which specific gene is affected, family history of cancer, the person’s age, and whether cancer has already developed.^[6]

People with mismatch repair deficiency—the condition caused by these mutations—face a greatly elevated risk of developing certain cancers, particularly colorectal cancer and endometrial cancer. The genetic instability caused by the faulty repair system creates a distinctive pattern called microsatellite instability, where short repetitive sequences of DNA become unstable and change length frequently. This pattern serves as a diagnostic marker that doctors use to identify when someone’s cancer is related to mismatch repair problems.^[8]

Standard Surveillance and Prevention Strategies

For people with confirmed mismatch repair gene mutations who have not yet developed cancer, the standard approach centers on intensive surveillance. This means more frequent screening tests starting at a younger age than typically recommended for the general population. Colonoscopy, which examines the inside of the large intestine, is usually recommended every one to two years beginning in the early twenties or even late teens, depending on family history. This aggressive screening schedule exists because colorectal cancer can develop quickly in people with these mutations, and catching precancerous polyps or very early cancers dramatically improves outcomes.^[3]

Women with these mutations face substantially increased risk of endometrial and ovarian cancers. Standard recommendations often include annual endometrial sampling and transvaginal ultrasound beginning in the late twenties or early thirties. However, because screening for these gynecological cancers is less reliable than colonoscopy for detecting early disease, many women choose to have their uterus and ovaries removed surgically once they have completed childbearing. This preventive surgery, called prophylactic hysterectomy with bilateral salpingo-oophorectomy, can substantially reduce cancer risk but requires careful discussion about timing, hormone replacement, and individual circumstances.^[6]

Screening for other associated cancers may also be recommended based on family history and which specific gene is mutated. Some people need regular upper endoscopy to check for stomach and small intestine cancers, periodic urinalysis to monitor for urinary tract cancers, and dermatological examinations for skin cancers. The exact surveillance protocol is tailored to the individual based on their specific genetic mutation and their family’s cancer history pattern.

Treatment When Cancer Develops: Traditional Approaches

When someone with a mismatch repair gene mutation develops cancer, they initially receive many of the same standard treatments as people with non-hereditary cancers. Surgery remains a cornerstone for removing tumors, and the specific surgical approach depends on the cancer type, location, and stage. For colorectal cancer, this might mean removing part of the colon along with nearby lymph nodes. The extent of surgery sometimes differs from standard approaches because people with these mutations face higher risk of developing additional cancers in the same organ or in other parts of the digestive tract.

Traditional chemotherapy has long been used to treat cancers associated with mismatch repair deficiency, particularly after surgery to eliminate any remaining cancer cells. However, research has revealed that mismatch repair deficient cancers respond differently to certain chemotherapy drugs than repair-proficient cancers. Some studies suggest that certain fluorouracil-based chemotherapy regimens—long considered standard for colorectal cancer—may be less effective or even potentially harmful in early-stage mismatch repair deficient tumors. This has led to careful evaluation of which chemotherapy protocols to use based on the tumor’s mismatch repair status.^[6]

Radiation therapy may be used in some situations, particularly for rectal cancers where radiation before surgery can shrink tumors and make them easier to remove. The decision to use radiation considers many factors including the cancer’s location, stage, and the person’s overall health and treatment goals. Side effects from radiation can include fatigue, skin changes in the treated area, and digestive problems if the abdomen or pelvis is being treated.

Immunotherapy: A Breakthrough for Mismatch Repair Deficient Cancers

One of the most significant developments in treating cancers caused by mismatch repair gene mutations involves harnessing the immune system. Tumors that develop in people with defective mismatch repair accumulate far more mutations than typical cancers. Each mutation can create abnormal proteins that the immune system might recognize as foreign—similar to how it recognizes bacteria or viruses. These abnormal proteins are called neoantigens, and mismatch repair deficient tumors are particularly rich in them.^[5]

The immune system should theoretically attack cells displaying these foreign-looking proteins, but cancer cells often find ways to shut down the immune response. They do this partly through molecules called checkpoint proteins, which normally act as brakes on the immune system to prevent it from attacking the body’s own tissues. Cancer cells exploit these checkpoint proteins to hide from immune attack. Drugs called immune checkpoint inhibitors release these brakes, allowing immune cells to recognize and destroy cancer cells.

The checkpoint inhibitor drugs that have shown particular promise for mismatch repair deficient cancers include pembrolizumab and nivolumab, which block a checkpoint protein called PD-1, and drugs that block PD-L1, another checkpoint molecule. Clinical trials have demonstrated remarkable responses in many patients with advanced mismatch repair deficient colorectal cancer and other tumor types. In some studies, approximately 40 to 50 percent of patients experienced significant tumor shrinkage, and importantly, responses often lasted for extended periods.^[5]

These immunotherapy drugs work differently than chemotherapy. Rather than directly poisoning cancer cells, they empower the patient’s own immune system to do the work. This means the side effect profile is quite different. Instead of typical chemotherapy effects like hair loss and severe nausea, immunotherapy can cause immune-related adverse events where the revved-up immune system sometimes attacks normal tissues. This can lead to inflammation in organs like the lungs, intestines, liver, or hormone-producing glands. Most of these side effects are manageable, especially when caught early, but they require careful monitoring throughout treatment.

Not every patient with mismatch repair deficient cancer responds to immunotherapy, and researchers continue investigating why some respond dramatically while others don’t benefit. Approximately 50 percent of patients don’t respond adequately to these treatments, highlighting the need for continued research into combination approaches and new strategies to overcome resistance.^[5]

Innovative Approaches Being Studied in Clinical Trials

Research laboratories and medical centers worldwide are actively investigating new treatment strategies specifically designed for cancers arising from mismatch repair defects. These investigations span from early-phase safety studies to large trials comparing new approaches against current standards. Understanding these emerging options helps patients and families appreciate what might become available in the coming years.

One major research direction involves combining different immunotherapy drugs to potentially boost response rates. Scientists are testing combinations of checkpoint inhibitors with different targets—for example, combining anti-PD-1 drugs with drugs blocking CTLA-4, another immune checkpoint. The theory is that blocking multiple immune brakes simultaneously might release a stronger anti-tumor response. Early trial results show promise but also indicate that combination immunotherapy increases the risk of immune-related side effects, requiring careful balance between effectiveness and safety.

Researchers are also investigating ways to combine immunotherapy with other treatment types. Some trials test immunotherapy alongside chemotherapy, exploring whether chemotherapy might make tumors more visible to the immune system or create an environment where checkpoint inhibitors work better. Other studies examine radiation combined with immunotherapy, based on evidence that radiation can sometimes release tumor antigens that help the immune system recognize cancer cells throughout the body—not just in the radiated area.

Another fascinating research area focuses on why some mismatch repair deficient tumors respond to immunotherapy while others resist it. Scientists have discovered that the tumor microenvironment—the complex mixture of blood vessels, supporting cells, and immune cells surrounding the cancer—plays a crucial role. Tumors with high numbers of immune cells already present, particularly T lymphocytes, tend to respond better to checkpoint inhibitors. Tumors with few immune cells, sometimes called “cold” tumors, often don’t respond well. Clinical trials are testing drugs that might turn cold tumors hot by attracting more immune cells or making the tumor environment more hospitable to immune attack.^[5]

Researchers are exploring personalized cancer vaccines tailored to each patient’s specific tumor mutations. Since mismatch repair deficient tumors create many abnormal proteins, scientists can identify the unique neoantigens in a person’s tumor and create a custom vaccine to train their immune system to attack cells displaying those exact proteins. These personalized vaccines are still in early clinical trials, but initial results suggest they can generate strong immune responses. When combined with checkpoint inhibitors, they might help more patients respond to treatment.

Some experimental approaches aim to restore mismatch repair function directly. While this remains technically challenging, laboratory studies are investigating ways to deliver functional copies of repair genes into cells or use small molecules to compensate for defective repair proteins. These approaches remain in very early research stages and are not yet tested in patients, but they represent a fundamentally different strategy than managing the consequences of repair deficiency.

Clinical trials studying these cancers are conducted at medical centers throughout the United States, Europe, and other regions. Patient eligibility depends on many factors including the specific cancer type, whether it’s newly diagnosed or recurrent, prior treatments received, and overall health status. Most trials require confirmation that the tumor is mismatch repair deficient, usually through testing that identifies microsatellite instability or loss of mismatch repair proteins in tumor tissue samples.^[5]

Most common treatment methods

• Intensive cancer surveillance
  • Frequent colonoscopy starting in early twenties to detect colorectal polyps and cancers
  • Annual gynecological screening for endometrial and ovarian cancers in women
  • Additional screening protocols based on family history and specific gene mutation
• Preventive surgery
  • Prophylactic removal of uterus and ovaries in women after childbearing is complete
  • Consideration of more extensive colon removal when colorectal cancer is diagnosed due to high risk of additional cancers
• Surgical tumor removal
  • Removal of cancerous tissue along with surrounding healthy tissue margins
  • Lymph node removal to check for cancer spread
  • Extent of surgery adjusted based on mutation carrier status and risk of additional tumors
• Immunotherapy with checkpoint inhibitors
  • Pembrolizumab and nivolumab targeting PD-1 checkpoint protein
  • Particularly effective for advanced mismatch repair deficient cancers
  • Works by releasing immune system brakes to allow attack on tumor cells
  • Response rates around 40-50% in clinical studies
• Chemotherapy
  • Used after surgery to eliminate remaining cancer cells
  • Specific regimens chosen based on mismatch repair status as some drugs less effective in repair-deficient tumors
  • Side effects include fatigue, nausea, increased infection risk, and temporary blood count changes
• Radiation therapy
  • Used for certain tumor locations, particularly rectal cancers
  • May be given before surgery to shrink tumors
  • Sometimes combined with immunotherapy in clinical trials